weekly_roundup

BioTechSign Daily Catalyst Roundup - October 30, 2026

Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisOctober 30, 2026

Daily Biotech Catalyst Digest: October 30, 2026

ITCI leads the current BioTechSign screen at 100.0/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
ITCIIntra-Cellular Therapies100.0Aclinical activity 100%
DCPHDeciphera Pharmaceuticals100.0Aclinical activity 100%
BGNEBeiGene Ltd100.0Apublication signal 100%, clinical activity 100%
AKBAAkebia Therapeutics87.2Aclinical activity 92%, short interest 50%
RGNXREGENXBIO Inc86.4Apublication signal 100%, clinical activity 100%, short interest 70%
SRPTSarepta Therapeutics85.9Aclinical activity 100%, short interest 70%, dilution risk 48%

Recent Grade-Change Queue

  • ABEO (Abeona Therapeutics Inc.) currently grades C with a 59.4/100 catalyst score. Main inputs: short interest 90%, clinical activity 62%, dilution risk 38%.
  • MNOV (Medicinova Inc) currently grades D with a 41.3/100 catalyst score. Main inputs: clinical activity 50%, dilution risk 26%, short interest 10%.
  • IMNM (Immunome, Inc.) currently grades D with a 40.4/100 catalyst score. Main inputs: clinical activity 54%, short interest 50%, PDUFA timing 35%.
  • INO (Inovio Pharmaceuticals, Inc.) currently grades D with a 42.5/100 catalyst score. Main inputs: dilution risk 87%, short interest 70%, clinical activity 25%.
  • ACTU (Actuate Therapeutics, Inc.) currently grades F with a 26.3/100 catalyst score. Main inputs: clinical activity 42%, short interest 30%, insider buying 0%.
  • LXEO (Lexeo Therapeutics, Inc.) currently grades C with a 51.6/100 catalyst score. Main inputs: short interest 90%, clinical activity 50%, dilution risk 42%.
  • BBIO (BridgeBio Pharma) currently grades C with a 50.4/100 catalyst score. Main inputs: PDUFA timing 90%, short interest 50%, dilution risk 35%.
  • TVRD (Tvardi Therapeutics, Inc.) currently grades D with a 36.1/100 catalyst score. Main inputs: dilution risk 86%, short interest 30%, clinical activity 21%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.